Skip to main content

Advertisement

SpringerLink
Log in

The Role of CD90 in the Differential Diagnosis of Pleural Malignant Mesothelioma, Pulmonary Carcinoma and Comparison with Calretının

  • Original Article
  • Published:
Pathology & Oncology Research

Abstract

Pleural Malignant Mesothelioma (MM) is a fatal disease that has been associated with asbestos exposure. Differential diagnosis between the pleural infiltration of pulmonary carcinomas and MM is rather difficult particularly for epitheloid type mesothelioma.We aimed to investigate the utility of CD90, a cancer stem cell marker, in the differential diagnosis of MM and lung carcinoma, its prognostic significance and compare its value with that of Calretinin. Ninety pathology specimens including MM (n:30), pulmonary adenocarcinoma (n:30) and pulmonary squamous cell carcinoma (n:30) were used in this study. Immunohistochemical comparision of CD 90 and Calretinin was made in all groups. Calretinin was positive in 20 cases with MM (64.5 %), and was negative in 10 (32.3 %). CD 90 was positive in 25 of these cases (80 %) and negative in 5 (16 %). On the other hand pulmonary adenocarcinomas and squamous cell carcinomas showed positivity with CD90, 63,6 % and 73 %, respectively. We think that CD 90 has no place in the differential diagnosis between mesothelioma and pulmonary carcinoma because of the low specificity in spite of the high sensitivity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Gueugnon F, Leclercq S, Blanquart C et al (2011) Identification of novel markers for the diagnosis of malignant pleural mesothelioma. Am J Pathol 178:1033–1042

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Panel V, Vyberg M, Weinreich UM et al (2015) The established and future biomarkers of malignant pleural mesothelioma. Cancer Treat Rev 41:486–495

    Article  Google Scholar 

  3. Ascoli V (2015) Pathologic diagnosis of malignant mesothelioma: chronological prospect and advent of recommendations and guidelines. Ann Ist Super Sanita 51(1):52–59

    PubMed  Google Scholar 

  4. Ucer O, Dagli AF, Kılıcarslan A et al (2013) Value of glut-1 and Koc markers in the differential diagnosis of reactive mesothelial hyperplasia, malignant mesothelioma, and pulmonary adenocarcinoma. Turkish J Pathol 29:94–100

    Article  Google Scholar 

  5. Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC (eds) (2004) World Health Organization classification of Tumours. Pathology and genetics of tumors of the lung, pleura, thymus and heart. IARC Press: Lyonn

  6. Kawamura K, Hiroshima K, Suzuki T et al (2013) CD 90 is a diagnostic marker to differentiate between malignant pleural mesothelioma and lung carcinoma with immunohistochemistry. Am J Clin Pathol 140:544–549

    Article  PubMed  Google Scholar 

  7. Amatya VJ, Takeshima Y, Kohno H et al (2009) Caveolin-1 is a novel immunohistochemical marker to differentiate epithelioid mesothelioma from lung adenocarcinoma. Histopathology 55:10–19

    Article  PubMed  Google Scholar 

  8. Cassoni P, Daniele L, Maldi E et al (2009) Caveolin-1 expression in lung carcinoma varies according to tumor histotype and is acquired de novo in brain metastases. Histopathology 55:20–27

    Article  PubMed  Google Scholar 

  9. Zieglee A, Cerciello F, Bigosch C et al (2012) Proteomic surface some analysis of mesothelioma. Lung Cancer 75:189–196

    Article  Google Scholar 

  10. Yilmaz G, Akyol G, Cakir A et al (2014) Investigation of diagnostic utility and expression profiles of stem cell markers (CD 133 and CD 90) in hepatocellular carcinoma, small cell dysplasia, and cirrhosis. Pathol Res Pract 210:419–425

    Article  CAS  PubMed  Google Scholar 

  11. Hermann PC, Bhaskar S, Cioffi M et al (2010) Cancer stem cells in solid tumors. Semin Cancer Biol 20:77–84

    Article  CAS  PubMed  Google Scholar 

  12. Ji J (2012) Wang Xw. Clinical implications of cancer stem cell biology in hepatocellular carcinoma. Semin Oncol 39:461–472

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Deniz H, Kibar Y, Guldur ME et al (2009) Is D2-40 a useful marker for distinguishing malignant mesothelioma from pulmonary adenocarcinoma and benign mesothelial proliferations? Pathol Res Pract 205:749–752

    Article  CAS  PubMed  Google Scholar 

  14. Chaouche-Mazouni S, Scherpereel A, Zaamoum R et al (2015) Claudin 3, 4, and 15 expressions in solid tumors of lung adenocarcinoma versus malignant pleural mesothelioma. Ann Diagn Pathol 19:193–197

    Article  PubMed  Google Scholar 

  15. Yaziji H, Battifora H, Barry TS et al (2006) Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity. Mod Pathol 19:514–523

    Article  CAS  PubMed  Google Scholar 

  16. Ordonez NG (2006) The diagnostic utility of immunohistochemistry in distinguishing between epithelioid mesothelioma and squamous carcinoma of the lung: a comparative study. Mod Pathol 19:417–428

    Article  PubMed  Google Scholar 

  17. Yang ZF, Ho DW, Ng MN et al (2008) Significance of CD 90+ cancer stem cells in human liver cancer. Cancer Cell 13:153–166

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Turgut Ozal Medical Center, Department of Pathology, Inonu University, 44280, Malatya, Turkey

    Nurhan Sahin, Ayse Nur Akatli & Emine Turkmen Samdanci

  2. Turgut Ozal Medical Center, Department of Thoracic Surgery, Inonu University, Malatya, Turkey

    Muhammet Reha Celik & Hakkı Ulutas

  3. Medical Faculty, Department of Biostatistic, Inonu University, Malatya, Turkey

    Cemil Colak

Authors
  1. Nurhan Sahin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ayse Nur Akatli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Muhammet Reha Celik
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hakkı Ulutas
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Emine Turkmen Samdanci
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Cemil Colak
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nurhan Sahin.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sahin, N., Akatli, A.N., Celik, M.R. et al. The Role of CD90 in the Differential Diagnosis of Pleural Malignant Mesothelioma, Pulmonary Carcinoma and Comparison with Calretının. Pathol. Oncol. Res. 23, 487–491 (2017). https://doi.org/10.1007/s12253-016-0135-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12253-016-0135-9

Keywords

Search

Navigation